Update on novel strategies to optimize cetuximab therapy in patients with metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 7, Issue 5, 2008, Pages 300-308

  Macarulla, Teresa ^a   Ramos, Francisco Javier ^a   Élez, Elena ^a   Capdevila, Jaume ^a   Peralta, Sergio ^a   Tabernero, Josep ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Bevacizumab; Epidermal growth factor receptor; Panitumumab; Skin toxicity; Wild type K ras

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ACNE; ADVANCED CANCER; ALLERGIC REACTION; ANGIOGENESIS; ASTHENIA; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DISEASE FREE SURVIVAL; DNA POLYMORPHISM; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FOOD AND DRUG ADMINISTRATION; GENERAL CONDITION IMPROVEMENT; HUMAN; NAUSEA; NEUTROPENIA; PARONYCHIA; PHARMACOGENOMICS; PREDICTION; PROGNOSIS; REVIEW; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 53849133072     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2008.n.039     Document Type: Review

References (53)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2008; 58:71-96.
2. Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Collaborative Group. BMJ 2000; 321:531-5.
3. O'Connell MJ. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. Cancer 1989; 63(6 suppl):1026-30.
4. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-14.
5. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-47.
6. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-37.
7. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 2001; 92:1331-46.
8. Adenis A, Aranda Aguilar E, Robin YM, et al. Expression of the epidermal growth factor receptor (EGFR or HER1) and human epidermal growth factor receptor 2 (HER2) in a large scale metastatic colorectal cancer (mCRC) trial. J Clin Oncol 2005; 23(16 suppl):278s (Abstract 3630).
9. Goldstein NI, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995; 1:1311-8.
10. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001; 19(18 suppl):32S-40S.
11. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21:2787-99.
12. Mendelsohn J, Baselga J. The EGF receptor family as targets for anticancer therapy. Oncogene 2000; 19:6550-65.
13. Venook A, Niedzwiecki D, Hollis D, et al. Phase III study of irinotecan/5-FU/LV (FOLFIRI) or oxaliplatin/5-FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. J Clin Oncol 2006; 24(18 suppl):148s (Abstract 3509).
14. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
15. Köehne C, Zaluski J, Chung Rong C, et al. Cetuximab plus FOLFIRI first-line in metastatic colorectal cancer (mCRC): the randomized phase III CRYSTAL trial. Ann Oncol 2007; 18(suppl 7):vii21 (Abstract O-0031).
16. Tabernero J, Van Cutsem E, Díaz-Rubio E, et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007; 25:5225-32.
17. Dittrich C, Hoehler T, Lordick F, et al. A phase I/II study of cetuximab in combination with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer (MCRC) expressing epidermal growth factor receptor (EGFR). Preliminary results. Ann Oncol 2006; 17(suppl 6):vi24 (Abstract O-019).
18. Schuch G, Staroslawska E, Nowacki M, et al. Cetuximab plus 5-FU/FA/ oxaliplatin (FOLFOX-4) in the first-line treatment of mCRC: OPUS, a phase II study. Ann Oncol 2007; 18(suppl 7):vii18 (Abstract O-0022).
19. Borner M, Koeberle D, Von Moos R, et al. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann Oncol 2008; 19:1288-92.
20. Colucci G, Giuliani F, Mattioli R, et al. FOLFOX4 + cetuximab in untreated patients with advanced colorectal cancer. A phase II study of the Gruppo Oncologico dell'Italia Meridionale (prot. GOIM 2402). J Clin Oncol 2006; 24(18 suppl):160s (Abstract 3559).
21. Dakhil S, Cosgriff T, Headley D, et al. Cetuximab + FOLFOX6 as first line therapy for metastatic colorectal cancer (An International Oncology Network study, I-03-002). J Clin Oncol 2006; 24(18 suppl):160s (Abstract 3557).
22. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45.
23. Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20:2a (Abstract 7).
24. Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-8.
25. Wilke H, Glynne-Jones R, Thaler J, et al. MABEL - a large multinational study of cetuximab plus irinotecan in metastatic colorectal cancer progressing on irinotecan. J Clin Oncol 2006; 24(18 suppl):158s (Abstract 3549).
26. Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colon carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006; 24:4914-21.
27. Sobrero A, Hochster H, Luppi G, et al. Cetuximab plus irinotecan in patients with MCRC who have failed prior oxaliplatin-based therapy: the EPIC trial. Ann Oncol 2007; 18(suppl 7):vii20 (Abstract O-0030).
28. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357:2040-8.
29. Saltz L, Kies M, Abbruzzese JL, et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignances. Proc Am Soc Clin Oncol 2003; 22:204 (Abstract 817).
30. Van Cutsem E, Peeters M, Gelderblom H, et al. Cetuximab dose-escalation in MCRC patients with no or slight skin reactions on standard treatment (EVEREST). Ann Oncol 2007; 18(suppl 7):vii22 (Abstract O-0034).
31. Hebbar N, Wacrenier A, Desauw C, et al. Lack of usefulness of epidermal growth factor receptor determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs 2006; 17:855-7.
32. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23:1803-10.
33. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6:257-8.
34. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25:3230-7.
35. Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutations status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66:3992-5.
36. Lièvre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26:374-9.
37. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67:2643-8.
38. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19:508-15.
39. Finocchiaro G, Cappuzzo F, Jänne PA, et al. EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer. J Clin Oncol 2007; 25(18 suppl):168s (Abstract 4021).
40. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96:1166-9.
41. Amado RG, Wolf M, Freeman D, et al. Panitumumab (pmab) efficacy and patient reported outcomes (PRO) in metastatic colorectal cancer (mCRC) patients (pts) with wild-type (WT) KRAS tumor status. Presented at: the American Society of Clinical Oncology: 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. Abstract 278.
42. Tabernero J, Cervantes A, Ciardiello F, et al. Correlation of efficacy to KRAS status (wt vs. mut) in patients (pts) with metastatic colorectal cancer (mCRC), treated with weekly (q1w) and q2w schedules of cetuximab combined with FOLFIRI. Presented at: the American Society of Clinical Oncology: 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. Abstract 435.
43. Freeman D, Juan T, Meropol NJ, et al. Association of somatic KRAS gene mutations and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving panitumumab monotherapy. Presented at: the 14th European Cancer Conference; September 23-27, 2007; Barcelona; Spain. Abstract 3014.
44. Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000; 6:3739-47.
45. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25:1539-44.
46. Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007; 25:4557-61.
47. Lenz H, Zhang W, Yang D, et al. Pharmacogenomic analysis of a randomized phase II trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Presented at: the American Society of Clinical Oncology: 2007 Gastrointestinal Cancers Symposium Symposium; January 19-21, 2007; Orlando, FL. Abstract 401.
48. Hecht JR, Mitchell E, Chidiac T, et al. An update analysis of safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) ± panitumumab (pmab) for fist-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE). Presented at: the American Society of Clinical Oncology: 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. Abstract 273.
49. Matar P, Rojo F, Cassia R, et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 2004; 10:6487-501.
50. Baselga J, Schöffski P, Rojo F, et al. A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and nonsmall cell lung cancer (NSCLC). J Clin Oncol 2006; 24(18 suppl):122s (Abstract 3006).
51. Tabernero J, Cervantes A, Martinelli E, et al. Optimal doses of cetuximab (C) given every two weeks (q2w): a phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and every q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2006; 24(18 suppl):142s (Abstract 3085).
52. Pfeiffer P, Nielsen D, Bjerregaard J, et al. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol 2008; 19:1141-5.
53. ACROSS Cooperative Group, Roca JM, Alonso V, et al. Cetuximab given every 2 weeks (q2w) plus irinotecan is an active and safe option for previously treated patients (pts) with metastatic colorectal cancer (MCRC). Presented at: the American Society of Clinical Oncology: 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. Abstract 388.